PMID- 1349896
OWN - NLM
STAT- MEDLINE
DCOM- 19920615
LR  - 20190629
VI  - 592
IP  - 1-2
DP  - 1992 Feb 21
TI  - Determination of the enantiomers of fenoldopam in human plasma by reversed-phase 
      high-performance liquid chromatography after chiral derivatization.
PG  - 317-22
AB  - Fenoldopam, a selective agonist at peripheral dopaminergic (DA-1) receptors, is 
      administered as a racemic mixture and, consequently, an indirect stereospecific 
      high-performance liquid chromatographic assay was developed to study the 
      disposition of the individual enantiomers in human subjects. Fenoldopam 
      enantiomers were extracted from alkalinized plasma into ethyl acetate prior to 
      precolumn derivatization with the chiral reagent 
      2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl isothiocyanate (GITC). The resulting 
      diastereomers were separated on a reversed-phase butylsilica column and 
      determined using triple-electrode coulometric detection. The limits of 
      determination and detection for the S- and R-enantiomers of fenoldopam were 0.5 
      and 0.25 ng/ml, respectively. A linear response was observed for (S)- and 
      (R)-fenoldopam concentrations ranging from 0.5 to 50 ng/ml in plasma. The 
      intra-day relative standard deviations (R.S.D.s) for the plasma assay at nominal 
      concentrations of 0.5, 5 and 50 ng/ml were 17.4, 5.2 and 6.9%, respectively, for 
      (S)-fenoldopam and 9.9, 6.2 and 7.4%, respectively, for (R)-fenoldopam. The 
      inter-day R.S.D.s of the method at these concentrations were 9.3, 7.7 and 7.4%, 
      respectively, for (S)-fenoldopam and 9.5, 1.9 and 7.3%, respectively, for 
      (R)-fenoldopam. The mean accuracy of the method at concentrations of 0.5, 5 and 
      50 ng/ml in plasma was found to be 106.4, 111.8 and 108.9%, respectively, for 
      (S)-fenoldopam and 116.2, 104.2 and 111.2%, respectively, for (R)-fenoldopam. The 
      assay developed was sufficiently sensitive, accurate and precise to support 
      pharmacokinetic studies in human subjects.
FAU - Boppana, V K
AU  - Boppana VK
AD  - Department of Drug Metabolism and Pharmacokinetics, SmithKline Beecham 
      Pharmaceuticals, King of Prussia, PA 19406.
FAU - Geschwindt, L
AU  - Geschwindt L
FAU - Cyronak, M J
AU  - Cyronak MJ
FAU - Rhodes, G
AU  - Rhodes G
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr
JT  - Journal of chromatography
JID - 0427043
RN  - 0 (Vasodilator Agents)
RN  - 67287-49-4 (2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine)
RN  - INU8H2KAWG (Fenoldopam)
SB  - IM
MH  - 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/*analogs & 
      derivatives/blood
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Fenoldopam
MH  - Humans
MH  - Male
MH  - Stereoisomerism
MH  - Vasodilator Agents/*blood
EDAT- 1992/02/21 00:00
MHDA- 1992/02/21 00:01
CRDT- 1992/02/21 00:00
PHST- 1992/02/21 00:00 [pubmed]
PHST- 1992/02/21 00:01 [medline]
PHST- 1992/02/21 00:00 [entrez]
AID - 10.1016/0021-9673(92)85102-y [doi]
PST - ppublish
SO  - J Chromatogr. 1992 Feb 21;592(1-2):317-22. doi: 10.1016/0021-9673(92)85102-y.